Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 24/5/2020
SIETES contiene 93008 citas

<< anterior 21 a 40 de 231 siguiente >>
Presentar resultados
Seleccionar todas
21.Tiene citas relacionadas
Katsiki N, Banach M. Statins and the risk of diabetes: the debate. Arch Intern Med 2012;172:895-6. [Ref.ID 93200]
Roberts H. Hormone therapy for menopausal symptoms. BMJ 2012;344:11. [Ref.ID 92352]
23. Cita con resumen
Kmietowicz Z. Articles disputing link between HRT and breast cancer spark criticism. BMJ 2012;344:1. [Ref.ID 92289]
25.Tiene citas relacionadas Cita con resumen
Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, Manson JE, Qiao Y, Liu S, Merriam PA, Rahily-Tierny C, Thomas F, Berger JS, Ockene JK, Curb JD, Ma Y. Statin use and risk of diabetes mellitus in postmenopausal women in the women's health initiative. Arch Intern Med 2012;172:144-52. [Ref.ID 92271]
28.Tiene citas relacionadas
Abrahamsen B, Sahota O. Do calcium plus vitamin D supplements increase cardiovascular risk?. BMJ 2011;342:934-5. [Ref.ID 90686]
29.Tiene citas relacionadas
Chlebowski RT, Stefanick ML, Anderson GL. Breast cancer in postmenopausal women after hormone therapy. In reply. JAMA 2011;305:466-7. [Ref.ID 90149]
30.Tiene citas relacionadas
Hermsmeyer RK, Kaski JC, Thompson TL. Breast cancer in postmenopausal women after hormone therapy. JAMA 2011;305:466. [Ref.ID 90148]
31.Tiene citas relacionadas
Baber R. Breast cancer in postmenopausal women after hormone therapy. JAMA 2011;305:466. [Ref.ID 90147]
32.Tiene citas relacionadas
Bach PB. Postmenopausal hormone therapy and breast cancer. An uncertain trade-off. JAMA 2010;304:1719-20. [Ref.ID 89534]
33.Tiene citas relacionadas Cita con resumen
Chlebowski BT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE, Johnson KC, Wactawski-Wende J, Ravdin PM, Schenken R, Hendrix SL, Rajkovic A, Rohan TE, Yasmeen S, Prentice RL, for the WHI Investigators. Estrogen plus progesting and breast cancer incidence and mortality in postmenopausal women. JAMA 2010;304:1684-92. [Ref.ID 89533]
34. Cita con resumen
Maalouf NM, Sato AH, Welch BJ, Howard BV, Cochrane BB, Sakhaee K, Robbins JA. Postmenopausal hormone use and the risk of nephrolithiasis. Arch Intern Med 2010;170:1678-85. [Ref.ID 89483]
35. Cita con resumen
Toh S, Hernández-Díaz S, Logan R, Rossouw JE, Hernán MA. Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial. Ann Intern Med 2010;152:211-7. [Ref.ID 87935]
36.Tiene citas relacionadas Cita con resumen
O'Connor C, Fiuzat M. Antidepressant use, depression, and poor cardiovascular outcomes. The chicken or the egg?. Arch Intern Med 2009;169:2140-1. [Ref.ID 87418]
37.Tiene citas relacionadas Cita con resumen
Smoller JW, Allison M, Cochrane BB, Curb JD, Perlis RH, Robinson JG, Rosal MC, Wenger NK, Wassertheil-Smoller S. Antidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women in the Women's Health Initiative study. Arch Intern Med 2009;169:2128-39. [Ref.ID 87417]
38. Cita con resumen
Brett AS. "Timing hypothesis" for hormone therapy: still viable, or time to let go?. Journal Watch 2009;29:153. [Ref.ID 86936]
39.Tiene citas relacionadas
Chlebowski RT, Schwartz AG, Wakelee H, Anderson GL, Stefanick ML, Manson JE, Rodabough RJ, Chien JW, Wactawski-Wende J, Gass M, Kotchen JM, Johnson KC, O'Sullivan MJ, Ockene JK, Chen C, Hubbell FA, for the Women's Health Initiative Investigators. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet 2009;374:1243-51. [Ref.ID 86903]
40.Tiene citas relacionadas
Ganti AK. Another nail in the coffin for hormone-replacement therapy?. Lancet 2009;374:1217-8. [Ref.ID 86892]
Seleccionar todas
<< anterior 21 a 40 de 231 siguiente >>